Apremilast
![Psoriasis (Rapid Review of TA368) [ID987]](http://data.docslib.org/img/264x/4789413b5d66da03fbf69f79f10c0ebc.webp)
Top View
- Celgene Fact Sheet
- Therapeutic Class Overview Psoriatic Arthritis Agents: Phosphodiesterase 4 Inhibitors
- Apremilast Is a Selective PDE4 Inhibitor with Regulatory Effects on Innate Immunity, Cellular Signalling (2014), 2 P.H
- Assessment Report for Otezla
- Apremilast (Otezla) Reference Number: ERX.SPMN.168 Effective Date: 10/2016 Last Review Date: 12/2016 Revision Log
- Olumiant (Baricitinib) Annual Review Date: 08/20/2020
- Apremilast Microemulsion As Topical Therapy for Local Inflammation: Design, Characterization and Efficacy Evaluation
- Otezla, INN-Apremilast
- 9.Fareesa Fatima, Roshan.S
- PRODUCT MONOGRAPH Protezla® Apremilast Tablets 10 Mg, 20 Mg, and 30 Mg Selective Immunosuppressant Amgen Canada Inc. 6775 Fi
- ATC/DDD Classification
- International Nonproprietary Names for Pharmaceutical Substances (INN)
- Pre - PA Allowance None ______
- 206088Orig1s000
- Auspar Attachment 1: Product Information for Otezla
- Commissioning Pathway for Pbr Excluded Drugs for Psoriasis Adult with Severe Psoriasis – Use Standard Systemic Therapies Including Ciclosporin, Methotrexate and PUVA
- Advice for Individuals Taking Immunosuppressive Treatments for Their Skin Condition We Appreciate This Is a Very Worrying Time F
- Efficacy and Safety of Apremilast in Chronic Cutaneous Sarcoidosis